{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:54:32Z","timestamp":1790409272082,"version":"4.1.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,2]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The phase 1\/2 BelaRd (belantamab mafodotin [belamaf], lenalidomide, and dexamethasone) study evaluated the efficacy and safety of belamaf combined with lenalidomide and dexamethasone in unfit and frail transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). Part 1 (n = 36) established a recommended belamaf phase 2 dose (RP2D) of 1.9 mg\/kg every 8 weeks (median follow-up, 39.3 months). In part 2, 30 patients were randomized 1:1 in group A (n = 15), where belamaf dosing was guided by ophthalmologist-assessed ocular adverse events (OAEs), whereas in group B (n = 15), belamaf dosing was based on hematologist-led vision-related anamnestic (VRA) tool and ophthalmologist-assessed grade \u22653 OAEs. Among the RP2D patients (n = 42), overall response rate was 97.6%, median progression-free survival (PFS)\/overall survival have not been reached yet, and the 18-month PFS and time to progression rates were 83.0% and 97.2%, respectively. Ocular toxicities were similar between assessments by hematologists and ophthalmologists, and no ophthalmologist withholding of a hematologist-led dosing occurred. Less than 1% of patients stopped driving\/reading because of OAEs. Median time to belamaf reinfusion was 13 weeks. Overall, BelaRd is an effective regimen for transplant-ineligible patients with NDMM and warrants a phase 3 study in this setting. OAEs\u2019 impact on quality of life appears limited, and implementation of the hematologist-led VRA tool may eventually reduce the necessity for ophthalmologist assessments. This trial was registered at www.clinicaltrials.gov as #NCT04808037.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031629","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T07:50:04Z","timestamp":1764921004000},"page":"1574-1583","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"first","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-1229","authenticated-orcid":false,"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9783","authenticated-orcid":false,"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4673-171X","authenticated-orcid":false,"given":"Panagiotis","family":"Malandrakis","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0618-8900","authenticated-orcid":false,"given":"Despina","family":"Fotiou","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Kanellias","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalini","family":"Migkou","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6926-0351","authenticated-orcid":false,"given":"Foteini","family":"Theodorakakou","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Spiliopoulou","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Solia","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Eleutherakis-Papaiakovou","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2002-1486","authenticated-orcid":false,"given":"Giorgos","family":"Psarros","sequence":"additional","affiliation":[{"name":"2Veeda Lifesciences, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"},{"name":"3Department of Medicine, Korea University, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2026040211213716100_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-025-01212-0","article-title":"The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development","volume":"15","author":"Mukhopadhyay","year":"2025","journal-title":"Blood Cancer J"},{"issue":"5","key":"2026040211213716100_bib2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2026040211213716100_bib3","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2024-200336","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed\/refractory multiple myeloma: overall survival analysis and updated efficacy outcomes of the phase 3 DREAMM-7 trial","volume":"144","author":"Hungria","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2026040211213716100_bib4","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"issue":"suppl 17","key":"2026040211213716100_bib5","doi-asserted-by":"crossref","first-page":"LBA105","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA105","article-title":"Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed\/refractory multiple myeloma (RRMM)","volume":"42","author":"Trudel","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026040211213716100_bib6","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"2026040211213716100_bib7","first-page":"2594","article-title":"Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I\/II study","volume":"109","author":"Terpos","year":"2024","journal-title":"Haematologica"},{"issue":"3","key":"2026040211213716100_bib8","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ajh.27219","article-title":"Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1\/2 study","volume":"99","author":"Gavriatopoulou","year":"2024","journal-title":"Am J Hematol"},{"issue":"12","key":"2026040211213716100_bib9","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"13","key":"2026040211213716100_bib10","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2026040211213716100_bib11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3390\/diagnostics10080559","article-title":"A review of dry eye questionnaires: measuring patient-reported outcomes and health-related quality of life","volume":"10","author":"Okumura","year":"2020","journal-title":"Diagnostics (Basel)"},{"issue":"8","key":"2026040211213716100_bib12","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"17","key":"2026040211213716100_bib13","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"2026040211213716100_bib14","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"2026040211213716100_bib15","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"issue":"4","key":"2026040211213716100_bib16","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41375-024-02505-2","article-title":"Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes","volume":"39","author":"Facon","year":"2025","journal-title":"Leukemia"},{"issue":"5","key":"2026040211213716100_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","article-title":"Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J"},{"issue":"5","key":"2026040211213716100_bib18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S1470-2045(25)00018-X","article-title":"Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"26","author":"Mateos","year":"2025","journal-title":"Lancet Oncol"},{"issue":"23","key":"2026040211213716100_bib19","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1002\/cncr.34987","article-title":"Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: Final analysis of the DREAMM-2 trial","volume":"129","author":"Nooka","year":"2023","journal-title":"Cancer"},{"issue":"22","key":"2026040211213716100_bib20","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1182\/bloodadvances.2025016949","article-title":"Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials","volume":"9","author":"Mateos","year":"2025","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026040211213716100_bib21","doi-asserted-by":"crossref","first-page":"7286","DOI":"10.1182\/blood-2022-162584","article-title":"Belantamab mafodotin in combination with Vrd for the treatment of newly diagnosed transplant eligible multiple myeloma patients: results from the phase II, open label, multicenter, GEM-BELA-Vrd trial","volume":"140","author":"Gonzalez-Calle","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2026040211213716100_bib22","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2024-198669","article-title":"Phase I study of belantamab mafodotin in combination with standard of care in transplant-ineligible newly diagnosed multiple myeloma: Dreamm-9 updated interim analysis","volume":"144","author":"Usmani","year":"2024","journal-title":"Blood"},{"issue":"10","key":"2026040211213716100_bib23","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/ajh.70015","article-title":"Practical guidance on clinical management of belantamab mafodotin-associated ocular events","volume":"100","author":"Terpos","year":"2025","journal-title":"Am J Hematol"},{"issue":"1","key":"2026040211213716100_bib24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-025-01259-z","article-title":"Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study","volume":"15","author":"Tan","year":"2025","journal-title":"Blood Cancer J"},{"issue":"6","key":"2026040211213716100_bib25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"2026040211213716100_bib26","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"2026040211213716100_bib27","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"2026040211213716100_bib28","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol"},{"issue":"19","key":"2026040211213716100_bib29","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2026040211213716100_bib30","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv"},{"issue":"8","key":"2026040211213716100_bib31","doi-asserted-by":"crossref","first-page":"e764","DOI":"10.1097\/HS9.0000000000000764","article-title":"Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, excluding those under anti-BCMA therapy","volume":"6","author":"Ntanasis-Stathopoulos","year":"2022","journal-title":"Hemasphere"},{"issue":"6","key":"2026040211213716100_bib32","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s41375-023-01920-1","article-title":"Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)","volume":"37","author":"Terpos","year":"2023","journal-title":"Leukemia"},{"issue":"2","key":"2026040211213716100_bib33","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/14\/1574\/2511747\/blood_bld-2025-031629-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/14\/1574\/2511747\/blood_bld-2025-031629-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:21:49Z","timestamp":1775143309000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/14\/1574\/556939\/Belantamab-mafodotin-lenalidomide-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":33,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,4,2]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031629","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,2]]},"published":{"date-parts":[[2026,4,2]]}}}